Clear Value Plus

Evidence-based cancer care and financial information at your fingertips

Connecticut Oncology Association
March 18, 2015
Addressing variability and cost with pathways

Example: cost and number of regimen options in colon cancer

Value Pathways powered by NCCN (6 options)

NCCN Guidelines (12 options)

‘All’ regimens\(^1\) (44 options)

Regimen cost (\$, thousands)

---

1 Supported by NCCN Guidelines/Compendium for care of colon cancer
Source: Clear Value Plus; Metastatic colon cancer patient
Clear Value Plus technology brings relevant information to the point of care

Clear Value Plus℠
- Flexible access to leading content:
  - NCCN Guidelines®
  - Value Pathways powered by NCCN™
  - Institution-specific or payer-specific
- Integrates with leading EHRs (iKnowMed, Epic, Varian, Elekta)
- Includes financial information
- Real-time reporting on compliance, performance and outcomes
Value Pathways powered by NCCN: Leadership in evidence-based medicine

- Evidence-based protocols to reduce unsubstantiated variability and hospitalizations
- Refinement of the NCCN Guidelines®
- Direct collaboration with NCCN physicians
- Selected based on efficacy, toxicity and cost
- Accessible for physicians through Clear Value Plus technology
EHR-integrated workflow - iKnowMed

1) ‘Order regimen’ from within iKM Progress Note
EHR-integrated workflow - iKnowMed

2) Clinical facts transferred to CVP, relevant additional data entered
EHR-integrated workflow - iKnowMed

3) Evidence-based treatment options displayed
### 4) Selected Regimen returned to iKM for ordering

<table>
<thead>
<tr>
<th>Give</th>
<th>Order</th>
<th>Dose</th>
<th>Calc. Dose</th>
<th>Schedule</th>
<th>Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✅</td>
<td>✅</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✅</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✅</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✅</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✅</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>✅</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EHR-integrated workflow - iKnowMed

5) All relevant details and summary returned to chart
EHR-integrated workflow – Varian ARIA

1) Embedded access to CVP in Varian Medical Systems ARIA® Medications tab
EHR-integrated workflow – Varian ARIA

2) Transfer clinical facts, supplement within CVP

Fill in missing facts
Please supply the following information to demonstrate concordance:

NRAS test results: show definitions

- Wild type
- Non-wild type
- Unknown

Primary Diagnosis: Colon Cancer
EHR-integrated workflow – Varian ARIA

3) Highlight NCCN Guidelines and evidence-based options

<table>
<thead>
<tr>
<th>Treatment Options</th>
<th>Value Pathway</th>
<th>NCCN Guideline</th>
<th>NCCN Category</th>
<th>Febrile Neutropenic Risk</th>
<th>Emetogenic Risk</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trial - Other</td>
<td>✓</td>
<td>✓</td>
<td>N/A</td>
<td></td>
<td></td>
<td>Show Options ▼</td>
</tr>
<tr>
<td>Capecitabine</td>
<td>✓</td>
<td>✓</td>
<td>2A</td>
<td>low</td>
<td>low</td>
<td>Show Options ▼</td>
</tr>
<tr>
<td>Capecitabine + Bevacizumab</td>
<td>✓</td>
<td>✓</td>
<td>2A</td>
<td>low</td>
<td>low</td>
<td>Show Options ▼</td>
</tr>
<tr>
<td>CapeOX</td>
<td>✓</td>
<td>✓</td>
<td>2A</td>
<td>low</td>
<td>moderate</td>
<td>Show Options ▼</td>
</tr>
<tr>
<td>CapeOX + Bevacizumab</td>
<td>✓</td>
<td>✓</td>
<td>2A</td>
<td>low</td>
<td>moderate</td>
<td>Show Options ▼</td>
</tr>
</tbody>
</table>
EHR-integrated workflow – Varian ARIA

4) Selected regimen returned to ARIA® for MO

Decision Success
Your decision has been sent to the EHR.

Order sent to EHR.
You may close this window.
EHR-integrated workflow – Varian ARIA

5) Regimen ordering proceeds in ARIA® for MO
Clear Value Plus enhances processes

Benefits for physicians and administrators

▪ **Strength of content:**
  ▪ NCCN Guidelines as content backbone
  ▪ Can show multiple Guidelines or pathways

▪ **Participate with confidence in multiple programs:**
  ▪ Anthem quality program
  ▪ CMS Oncology Care Model
  ▪ Aetna Oncology Medical Home

▪ **Ease of use:**
  ▪ Workflow integration
  ▪ Real-time, self-serve reports
Simplify today’s demands and position for tomorrow

- Simplify existing payer requirements
- Collaborate in shared savings / risk
- Enhanced clinical documentation
- Support value-based contracting
- Create greater financial visibility
- Clinical quality and value reporting

Clear Value Plus

© 2013 McKesson Specialty Health. All Rights Reserved
Clear Value Plus demonstration
## Patient roster home screen

### Durham Oncology Practice

<table>
<thead>
<tr>
<th>Name</th>
<th>MRN</th>
<th>Disease</th>
<th>Provider</th>
<th>Latest Decision</th>
<th>Pending Decisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norman New</td>
<td>UTPT02-02</td>
<td>Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Peter Benton, MD</td>
<td>2014-12-08</td>
<td></td>
</tr>
<tr>
<td>Barney Rubble</td>
<td>891234</td>
<td>Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Marcus Neubauer, MD</td>
<td>2014-12-06</td>
<td></td>
</tr>
<tr>
<td>Lan Nguyen</td>
<td>123467</td>
<td>Multiple Myeloma</td>
<td>Benjamin Pierce, MD</td>
<td>2014-12-04</td>
<td></td>
</tr>
<tr>
<td>James Jenkins</td>
<td>12344</td>
<td>Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Mark Greene, MD</td>
<td>2014-11-20</td>
<td></td>
</tr>
<tr>
<td>zztest Fred</td>
<td>2211</td>
<td>Breast Cancer (Invasive)</td>
<td>Fred Ronnaud, MD</td>
<td>2014-11-14</td>
<td></td>
</tr>
<tr>
<td>George Rondell</td>
<td>CVPDEMO03</td>
<td>Prostate Cancer</td>
<td>Marcus Neubauer, MD</td>
<td>2014-11-07</td>
<td></td>
</tr>
<tr>
<td>Amy Asco</td>
<td>12345</td>
<td>Colon Cancer</td>
<td>Amy Bartz</td>
<td>2014-11-04</td>
<td></td>
</tr>
<tr>
<td>Barney Benton</td>
<td>123499</td>
<td>Non-Hodgkin's Lymphomas</td>
<td>Marcus Neubauer, MD</td>
<td>2014-11-02</td>
<td></td>
</tr>
<tr>
<td>Norman Newer</td>
<td>898688</td>
<td>Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Peter Benton, MD</td>
<td>2014-10-22</td>
<td></td>
</tr>
<tr>
<td>Harold James</td>
<td>1111</td>
<td>Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Peter Benton, MD</td>
<td>2014-10-08</td>
<td></td>
</tr>
<tr>
<td>Sally Thomas</td>
<td>12121</td>
<td>Ovarian Cancer</td>
<td>Peter Benton, MD</td>
<td>2014-10-08</td>
<td></td>
</tr>
<tr>
<td>Sonia Baines</td>
<td>8035710521</td>
<td>Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Test Provider, MD</td>
<td>2014-09-29</td>
<td></td>
</tr>
</tbody>
</table>

*Powered By NCCN*
New treatment decision – clinical data entry
New treatment decision – clinical data entry
New treatment decision – treatment ‘choice board’ – medical info
New treatment decision – treatment ‘choice board’ – financial info

<table>
<thead>
<tr>
<th>Clinical Trials</th>
<th>ASP + 4.3%</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trial - Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment Options</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cisplatin + Vinorelbine</td>
<td>$1,200</td>
<td>Show Options ▼</td>
</tr>
<tr>
<td>Paclitaxel + Carboplatin</td>
<td>$600</td>
<td>Show Options ▼</td>
</tr>
<tr>
<td>Cisplatin + Docetaxel</td>
<td>$2,300</td>
<td>Show Options ▼</td>
</tr>
<tr>
<td>Cisplatin + Etoposide</td>
<td>$400</td>
<td>Show Options ▼</td>
</tr>
<tr>
<td>Cisplatin + Gemcitabine</td>
<td>$900</td>
<td>Show Options ▼</td>
</tr>
<tr>
<td>Cisplatin + Pemetrexed</td>
<td>$22,100</td>
<td>Show Options ▼</td>
</tr>
<tr>
<td>Cisplatin + Vinblastine</td>
<td>$400</td>
<td>Show Options ▼</td>
</tr>
</tbody>
</table>

© 2013 McKesson Specialty Health. All Rights Reserved
Payer-specific content - select insurance

Patient Primary Insurance

Insurance company name

- Anthem

[Save]
### Payer-specific content – payer pathways

#### Clear Value Plus℠

**Treatment: Adjuvant/Post-operative therapy**

<table>
<thead>
<tr>
<th>Clinical Trials</th>
<th>Value Pathway</th>
<th>NCCN Guideline</th>
<th>Anthen Pathway</th>
<th>NCCN Pathway</th>
<th>Emetic Risk</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trial - Other</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Diagnosis

- **Primary Diagnosis**: Non-Small Cell Lung Cancer (NSCLC)

#### Staging Information

- **Treatment Intent**: Post-operative/Adjuvant
- **Stage at diagnosis**: Stage IIA
- **Pathologic T-value**: pT2a
- **Pathologic N-value**: pN2
- **M-value**: M0

#### NSCLC Factors

- **Histology**: Non-sequamous

---

© 2013 McKesson Specialty Health. All Rights Reserved
Reporting – Compliance trend (NCCN Guidelines) – filtered by provider

NOTE: Demo data – does not imply actual compliance results

Proprietary and confidential © 2013 McKesson Specialty Health. All Rights Reserved